Understanding how the Body Responds to Weight Loss Medications
The purpose of this research study is to better understand how the body responds to nutrient stimulated hormone receptor agonist (NuSH RA) medications, commonly prescribed for weight loss.
Why this Research Matters
This is a one-year study, with participation lasting up to 14 months to account for scheduling visits. This study will have a maximum of three in-person visits each taking approximately 1-1½ hours to complete. You will undergo assessments of your body weight, body composition, bone density, fasting blood laboratory values, physical activity levels, dietary intake, and gut microbiome.
Who can Participate
You may qualify for this study if you: • Are an adult 18-65 years old • Have a BMI of at least 27 • Plan to seek a new prescription for a NuSH RA medication (e.g., Wegovy/semaglutide, Zepbound/tirzepatide, or other new NuSH RA drugs approved by the FDA during this study) for weight loss and are able to obtain the medication through insurance and/or direct pay Please complete our pre-screening survey to see if you are eligible to join our study: https://redcap.link/nush
Study ID
Protocol Number: 25-2231
Meet the Team
Principal Investigator